Rosuvastatin 10 mg/day was more effective than pravastatin 40 mg/day on LDL-c and triglyceride levels in HIV-1-infected patients receiving a boosted protease inhibitor.

No abstract

SAFEHEART-risk equation can now be used in other European population of HeFH patients to predict CV events.• The cholesterol-year-score is a robust predictor of CV events in HeFH patients.• SAFEHEART-RE and the cholesterol-year-score are valid in primary prevention heFH patients.

No abstract